Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
December 2025: Emcure Pharmaceuticals launched Poviztra, a semaglutide-based weight-loss therapy, at USD 106 (INR 8,790) per month, becoming the first Indian company to commercialize Novo Nordisks molecule for obesity
Depending on the clinicians decision, treatment may include a compounded GLP-1 or GLP-1/GIP medication
Novo Nordisks Ozempic is approved by the FDA to treat type-2 diabetes, and it has been widely prescribed for the off-label benefit of weight loss
Post-appendectomy intra-abdominal abscess
Human islets were obtained from the Integrated islet Distribution Program
US$ 21.23
US$ 27.32
US$ 20.02
US$ 25.42
US$ 29.60
US$ 26.28
US$ 24.04
